Article Text

Download PDFPDF

248 Validation of the adjusted global anti-phospholipid syndrome score in the argentine population
  1. Lucila Garcia1,
  2. Sofia Velloso1,
  3. Victoria Martire1,
  4. Florencia Savy1,
  5. Fernando Arizpe1,
  6. Nadia Garcia1,
  7. Adriana Testi1,
  8. Claudia Pena1,
  9. Carolina Isnardi2,
  10. Dafne Capelusnik2,
  11. Victoria Collado3,
  12. Florencia Rodriguez4,
  13. Susana Mazza5,
  14. Yessika Soria Curi5 and
  15. Mercedes Garcia1
  1. 1HIGA San Martin La Plata
  2. 2Instituto de Rehabilitacion Psicofisica
  3. 3Consultorio Privado
  4. 4Hospital Bernardino Rivadavia
  5. 5Hospital Padilla


Background Assessment of risk both for pregnancy morbidity and thrombosis in the presence of antiphospholipid antibodies (aPL) is still a challenge.

Objective to assess the performance of adjusted Global Anti-phospholipid Syndrome Score (aGAPSS) in predicting thrombosis in the setting of an external cohort study in patients with Systemic Lupus Erythematosus (SLE).

Methods Consecutive SLE patients from five rheumatology centers were included. Conventional cardiovascular risk factors were recorded as well as other underlying factors for thrombosis. Immunological tests were also recorded: ANA, anti-DNA, anti-SSA/SSB, anti-RNP, anti-Sm and aPL (Lupus Anticoagulant (LA), anti-cardiolipin (aCL) and 2 Glycoprotein I (2GPI). Medications received by patients were hydroxicloroquine, aspirin and anticoagulants. aGAPSS was calculated for each patient using a point system: 1 for arterial hypertension, 3 for dyslipidemia, 4 for LA and B2GPI and 5 for aCL. The score ranges from 0 to 17. The discriminative ability of aGAPSS was calculated by measuring the area under the receiver operating characteristic (ROC) curve (AUC). Multivariate survival analysis was performed using the proportional hazards model to identify the association of the aGAPSS cut-off value with thrombotic events adjusted to potential confounding factors. Multivariate logistic regression analysis was performed to examine the impact of multiple cardiovascular risk factors and laboratory parameters on the occurrence of thrombosis. A 95% confidence interval (CI) was selected and a p value<0.05 was considered significant.

Abstract 248 Table 1

Detailed report of sensitivity and specificity

Abstract 248 Figure 1

ROC Curve

Results Information was collected from 216 SLE patients ( 89.8% women, mean age at SLE diagnosis of 31 years (SD ±10.5). Ninety patients (41.6%) presented thrombotic and/or pregnancy complications. Forty-three patients (19.9%) presented at least one thrombotic episode (53 events; 28 arterial and 25 venous thromboses). Sixty women (30.9%) presented at least one pregnancy complication (81 events; 34 miscarriages, 28 fetal deaths and 19 premature deliveries). Median aGAPSS was significantly higher in patients who experienced a thrombotic event compared with those who had not [4 (IQR 1–9) versus 1 (IQR 0–5); p 0.001]. The AUC showed that aGAPSS 8 presented the best diagnostic accuracy [0.63 (CI95% 0.55–0.70) p 0.03] with 30% sensitivity and 82.5% specificity. Multivariate analysis indicated aGAPSS 8 was an independent predictor of thrombosis [OR: 2.1 (CI95% 1.03–4.12) p 0.04].

Conclusions This score is a simple tool to predict risk of thrombosis in SLE patients in daily practice. The use of aGAPSS could change the non-pharmacological and pharmacological treatment in higher risk patients to improve survival.

Funding Source(s): None

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.